FIGURE 5.

LL-37 inhibited the growth of pancreatic tumors in vivo. (A) The subcutaneous tumor diameters were measured every 3 days, and the tumor volumes were calculated using the formula: (short diameter)² × (long diameter) × 0.5. *p < 0.05, **p < 0.01 for LL-37 20 mg/kg vs. control group; ^# p < 0.05, ^## p < 0.01 for gemcitabine vs. control group. (B) The tumor weights in the control group, positive drug group (gemcitabine 50 mg/kg), low-dose LL-37 (10 mg/kg) group and high-dose LL-37 (20 mg/kg) group. **p < 0.01 vs. control group. (C) Tumor tissues from mice in different groups were subjected to a TUNEL apoptosis assay. (D) Immunohistochemistry analysis to detect Ki67 and LC3Ⅱ expression in the tumor tissues of mice in different groups (scale bar = 50 μm, magnification × 400). (E) The body weights were measured every 3 days ^# p < 0.05, ^## p < 0.01 gemcitabine vs. control group. After treatment for 14 days, the hematocrit (F) and white blood cells (G) in the peripheral blood were evaluated. *p < 0.05, **p < 0.01 vs. gemcitabine group.